Nexstim Plc (“Nexstim” or “Company”) has received order for an NBS 6 system from a distributor.
NBS 6 is a new combination system built on Nexstim’s unique, clinically established E-field navigated TMS (transcranial magnetic stimulation) technology, with a modular system concept that allows system capabilities to expand over time and be highly customized based on a customer’s research or clinical interests.
In October 2025, the Nexstim received MDR (Regulation (EU) 2017/745) certification for the NBS 6 for the pre-procedural mapping of the speech and motor cortices of the brain. The NBS 6 system is also CE-marked for the treatment of major depression and chronic neuropathic pain in the EU. The system ordered includes both diagnostic and therapy modules.
Mikko Karvinen, CEO of Nexstim, comments: “We are proud to see the NBS 6 fulfilling its promise as a versatile platform for both therapy and diagnostics. The launch of diagnostic capabilities in October was one of our key strategic objectives for 2025, and this order demonstrates the growing confidence in our technology. We are honored to provide technology that empowers clinicians to make informed, responsible decisions for their patients.”